Cargando…

Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)

BACKGROUND: Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. METHODS: We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Talaei, Mohammad, Faustini, Sian, Holt, Hayley, Jolliffe, David A., Vivaldi, Giulia, Greenig, Matthew, Perdek, Natalia, Maltby, Sheena, Bigogno, Carola M., Symons, Jane, Davies, Gwyneth A., Lyons, Ronan A., Griffiths, Christopher J., Kee, Frank, Sheikh, Aziz, Richter, Alex G., Shaheen, Seif O., Martineau, Adrian R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860623/
https://www.ncbi.nlm.nih.gov/pubmed/35189888
http://dx.doi.org/10.1186/s12916-022-02286-4
_version_ 1784654717350051840
author Talaei, Mohammad
Faustini, Sian
Holt, Hayley
Jolliffe, David A.
Vivaldi, Giulia
Greenig, Matthew
Perdek, Natalia
Maltby, Sheena
Bigogno, Carola M.
Symons, Jane
Davies, Gwyneth A.
Lyons, Ronan A.
Griffiths, Christopher J.
Kee, Frank
Sheikh, Aziz
Richter, Alex G.
Shaheen, Seif O.
Martineau, Adrian R.
author_facet Talaei, Mohammad
Faustini, Sian
Holt, Hayley
Jolliffe, David A.
Vivaldi, Giulia
Greenig, Matthew
Perdek, Natalia
Maltby, Sheena
Bigogno, Carola M.
Symons, Jane
Davies, Gwyneth A.
Lyons, Ronan A.
Griffiths, Christopher J.
Kee, Frank
Sheikh, Aziz
Richter, Alex G.
Shaheen, Seif O.
Martineau, Adrian R.
author_sort Talaei, Mohammad
collection PubMed
description BACKGROUND: Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. METHODS: We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a positive swab test result for SARS-CoV-2 prior to enrolment. Information on 88 potential sociodemographic, behavioural, nutritional, clinical and pharmacological risk factors was obtained through online questionnaires, and combined IgG/IgA/IgM responses to SARS-CoV-2 spike glycoprotein were determined in dried blood spots obtained between November 6, 2020, and April 18, 2021. We used logistic and linear regression to estimate adjusted odds ratios (aORs) and adjusted geometric mean ratios (aGMRs) for potential determinants of SARS-CoV-2 seropositivity (all participants) and antibody titres (seropositive participants only), respectively. RESULTS: Of 11,130 participants, 1696 (15.2%) were seropositive. Factors independently associated with  higher risk of SARS-CoV-2 seropositivity included frontline health/care occupation (aOR 1.86, 95% CI 1.48–2.33), international travel (1.20, 1.07–1.35), number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.29, 1.06–1.57, P-trend = 0.01), body mass index (BMI) ≥ 25 vs. < 25 kg/m(2) (1.24, 1.11–1.39), South Asian vs. White ethnicity (1.65, 1.10–2.49) and alcohol consumption ≥15 vs. 0 units/week (1.23, 1.04–1.46). Light physical exercise associated with  lower risk (0.80, 0.70–0.93, for ≥ 10 vs. 0–4 h/week). Among seropositive participants, higher titres of anti-Spike antibodies associated with factors including BMI ≥ 30 vs. < 25 kg/m(2) (aGMR 1.10, 1.02–1.19), South Asian vs. White ethnicity (1.22, 1.04–1.44), frontline health/care occupation (1.24, 95% CI 1.11–1.39), international travel (1.11, 1.05–1.16) and number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.12, 1.02–1.23, P-trend = 0.01); these associations were not substantially attenuated by adjustment for COVID-19 disease severity. CONCLUSIONS: Higher alcohol consumption and lower light physical exercise represent new modifiable risk factors for SARS-CoV-2 infection. Recognised associations between South Asian ethnic origin and obesity and higher risk of SARS-CoV-2 seropositivity were independent of other sociodemographic, behavioural, nutritional, clinical, and pharmacological factors investigated. Among seropositive participants, higher titres of anti-Spike antibodies in people of South Asian ancestry and in obese people were not explained by greater COVID-19 disease severity in these groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02286-4.
format Online
Article
Text
id pubmed-8860623
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88606232022-02-22 Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK) Talaei, Mohammad Faustini, Sian Holt, Hayley Jolliffe, David A. Vivaldi, Giulia Greenig, Matthew Perdek, Natalia Maltby, Sheena Bigogno, Carola M. Symons, Jane Davies, Gwyneth A. Lyons, Ronan A. Griffiths, Christopher J. Kee, Frank Sheikh, Aziz Richter, Alex G. Shaheen, Seif O. Martineau, Adrian R. BMC Med Research Article BACKGROUND: Prospective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking. METHODS: We did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a positive swab test result for SARS-CoV-2 prior to enrolment. Information on 88 potential sociodemographic, behavioural, nutritional, clinical and pharmacological risk factors was obtained through online questionnaires, and combined IgG/IgA/IgM responses to SARS-CoV-2 spike glycoprotein were determined in dried blood spots obtained between November 6, 2020, and April 18, 2021. We used logistic and linear regression to estimate adjusted odds ratios (aORs) and adjusted geometric mean ratios (aGMRs) for potential determinants of SARS-CoV-2 seropositivity (all participants) and antibody titres (seropositive participants only), respectively. RESULTS: Of 11,130 participants, 1696 (15.2%) were seropositive. Factors independently associated with  higher risk of SARS-CoV-2 seropositivity included frontline health/care occupation (aOR 1.86, 95% CI 1.48–2.33), international travel (1.20, 1.07–1.35), number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.29, 1.06–1.57, P-trend = 0.01), body mass index (BMI) ≥ 25 vs. < 25 kg/m(2) (1.24, 1.11–1.39), South Asian vs. White ethnicity (1.65, 1.10–2.49) and alcohol consumption ≥15 vs. 0 units/week (1.23, 1.04–1.46). Light physical exercise associated with  lower risk (0.80, 0.70–0.93, for ≥ 10 vs. 0–4 h/week). Among seropositive participants, higher titres of anti-Spike antibodies associated with factors including BMI ≥ 30 vs. < 25 kg/m(2) (aGMR 1.10, 1.02–1.19), South Asian vs. White ethnicity (1.22, 1.04–1.44), frontline health/care occupation (1.24, 95% CI 1.11–1.39), international travel (1.11, 1.05–1.16) and number of visits to shops and other indoor public places (≥ 5 vs. 0/week: 1.12, 1.02–1.23, P-trend = 0.01); these associations were not substantially attenuated by adjustment for COVID-19 disease severity. CONCLUSIONS: Higher alcohol consumption and lower light physical exercise represent new modifiable risk factors for SARS-CoV-2 infection. Recognised associations between South Asian ethnic origin and obesity and higher risk of SARS-CoV-2 seropositivity were independent of other sociodemographic, behavioural, nutritional, clinical, and pharmacological factors investigated. Among seropositive participants, higher titres of anti-Spike antibodies in people of South Asian ancestry and in obese people were not explained by greater COVID-19 disease severity in these groups. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12916-022-02286-4. BioMed Central 2022-02-22 /pmc/articles/PMC8860623/ /pubmed/35189888 http://dx.doi.org/10.1186/s12916-022-02286-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Talaei, Mohammad
Faustini, Sian
Holt, Hayley
Jolliffe, David A.
Vivaldi, Giulia
Greenig, Matthew
Perdek, Natalia
Maltby, Sheena
Bigogno, Carola M.
Symons, Jane
Davies, Gwyneth A.
Lyons, Ronan A.
Griffiths, Christopher J.
Kee, Frank
Sheikh, Aziz
Richter, Alex G.
Shaheen, Seif O.
Martineau, Adrian R.
Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
title Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
title_full Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
title_fullStr Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
title_full_unstemmed Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
title_short Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK)
title_sort determinants of pre-vaccination antibody responses to sars-cov-2: a population-based longitudinal study (covidence uk)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860623/
https://www.ncbi.nlm.nih.gov/pubmed/35189888
http://dx.doi.org/10.1186/s12916-022-02286-4
work_keys_str_mv AT talaeimohammad determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT faustinisian determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT holthayley determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT jolliffedavida determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT vivaldigiulia determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT greenigmatthew determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT perdeknatalia determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT maltbysheena determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT bigognocarolam determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT symonsjane determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT daviesgwynetha determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT lyonsronana determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT griffithschristopherj determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT keefrank determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT sheikhaziz determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT richteralexg determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT shaheenseifo determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk
AT martineauadrianr determinantsofprevaccinationantibodyresponsestosarscov2apopulationbasedlongitudinalstudycovidenceuk